Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac605
This study reported the long-term efficacy, safety, and tolerability of RZB through 52 weeks of treatment in KEEPsAKE 2. In doing so it demonstrated long-term, durable efficacy of risankizumab in improving symptom control, physical function and quality of life in patients with active PsA who were csDMARD-IR or Bio-IR.
Additionally, risankizumab was well tolerated, and the long-term safety profile was generally consistent with that observed at week 24. The KEEPsAKE 2 trial is ongoing, and the long-term efficacy and safety of risankizumab in PsA will continue to be evaluated.